• White light cystoscopy (“WLC”) is the most commonly used procedure to detect non-muscle invasive bladder cancer (“NMIBC”)
• Despite its prevalence, WLC is not the most effective method and contributes to a high bladder cancer recurrence rate
• Blue light cystoscopy (“BLC”) is a more recent and highly effective method, but the high cost of equipment and skill level has impeded its uptake among hospitals
• Imagin Medical believes the i/Blue(TM) Imaging System , which displays white and blue light images side by side, will address these issues
• It eliminates the need to purchase new cystoscopes. The i/Blue System’s dual-view camera head can attach to almost any cystoscope, lowering the cost of entry
• i/Blue Imaging System is a cost saver for hospitals and patients

The benefits of blue light cystoscopy (“BLC”) have been documented since 2010, when the FDA first approved the use of hexaminolevulinate HCL (“HAL”), an imaging agent that, when absorbed by cancerous cells, distinguishes them from healthy cells when exposed to blue light. However, despite this knowledge being in the public domain and the American Urology Association recommending the use of blue light, its uptake in the visualization, location, and subsequent resection of tumors in the bladder has been slow.

According to Imagin Medical (CSE: IME) (OTCQB: IMEXF), a company focusing on establishing a new standard of care in visualizing cancer, “Despite the American Urological Association’s recommendation in favor of using BLC, the technology is used in 10% of such procedures because of the high cost of equipment and the challenges surgeons face in switching back and forth between white light and blue light images to locate and resect the tumors,” CEO Jim Hutchens wrote in an article published on HealthTech Hot Spot (https://ibn.fm/DKhCy).

The high cost of BLC equipment has influenced the reliance on white light, which is responsible for a high recurrence of over 50% in patients with non-muscle invasive bladder cancer (“NMIBC”). NMIBC is the most common form of bladder cancer, with between 70% and 75% of all cases falling into this category. The other type is muscle-invasive bladder cancer (“MICB”) and occurs when NMIBC progresses. Further, over 600,000 people continuously live in fear of recurrence.

While the American Cancer Society notes that the survival rate for patients with NMIBC is 96% (https://ibn.fm/HDlGE), the high recurrence rate means that in the future, all patients must be monitored and more than 50%  need surgery again if and when the bladder cancer resurfaces. The high cost of treatment further makes the alarming statistics more disconcerting.

The average cost of bladder cancer treatment was $65,158 in 2005, while the lifetime cost of treating bladder cancer ranged between $99,270 and $120,684 for the same period. With the increase in the inflation rate and cost of living since then, the more recent figures are likely higher. Notably, 60% of the average cost went into surveillance and treatment of recurrences (https://ibn.fm/CMQrl). This means that white light cystoscopy (“WLC”) contributes to the high the cost of treating bladder cancer, yet hospitals are reluctant to switch to blue light because the equipment is expensive and a higher level of training is required. In this regard, the cost of bladder cancer treatment is high for both the patients and the hospitals.

However, Imagin Medical Inc. aims to rectify this problem with the i/Blue(TM) Imaging System, its first product in its quest to establish new ways of visualizing cancer. The i/Blue Imaging System addresses the shortfalls of both white and blue light cystoscopies. It uses a dual-view camera head that attaches to any cystoscope and houses two highly sensitive cameras with sophisticated optical filters. that separate white and blue light images. This product goes a step further by displaying the separated white and blue light images side by side. With the i/Blue Imaging System, a physician need not alternate between these two images when conducting surgeries, as is the case with existing BLC equipment. As such, the product addresses the limitations associated with BLC.

By displaying the blue light image that shows the highlighted cancer cells alongside the white light image that shows the full landscape of the bladder, the i/Blue Imaging System will provide surgeons with improved visualization to locate and resect tumors. The overall result is a reduction in the cost of treatment as detailed in a report by Urology Times, which showed that using BLC in conjunction with white light “lowered costs by $4,660 over five years compared with use of white light cystoscopy alone” (https://ibn.fm/FK2Ck).

Further, the i/Blue Imaging System’s camera head can be attached to any cystoscope, meaning that a hospital need not buy new cystoscope to use the blue light fluorescent technology. Imagin Medical’s product, which will create a win-win scenario for everyone involved, is currently in the manufacturing stage. following the selection of a contract manufacturer in late 2020 (https://ibn.fm/HQKhQ).

For more information, visit the company’s website at www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

• POCUS enables patients to receive timely care in more comfortable, accessible surroundings
• Sonography improves accuracy, safety of emergency medical procedures
• MediScan specializes in medical imaging products for acute, emergency medical situations

POCUS, or point of care ultrasound, is a medical practice that allows trained medical personnel to use ultrasound to treat and care for patients — regardless of where those patients are, noted a recent blog (https://ibn.fm/7zRVb) released by Healthtech Solutions (OTC: HLTT). HLTT’s wholly owned subsidiary, MediScan is the provider of an affordable high-definition 3D ultrasound device that can assist in this practice. “POCUS enables patients to get timely care without them having to go through the adversity of visiting the hospital, especially in an emergency. It also enables professionals to give intrinsic care to the patients, in a non-invasive manner,” the article reports. “Ultrasound can help a doctor diagnose the patient in real time. “Combined with the patient’s history and his current medical condition, a doctor can then suggest the best treatment for the patient,” the article continues. “Ultrasound can be a boon that highly benefits in an emergency when constantly monitoring the patient’s situation becomes necessary. Moreover, sonography improves the accuracy and safety of emergency medical procedures.” The blog noted that most patients coming to the emergency room need immediate treatment. Often that treatment can’t be determined without careful evaluation; ultrasound is frequently an essential part of that evaluation process. Patients with a wide array of issues — from trauma and cardiac arrest to abdominal pain and hypotension — may need the quick, accurate assessment that comes from a high-quality ultrasound. MediScan specializes in medical imaging products for acute, emergency medical situations such as this; MediScan products are also invaluable in long-term care settings as POCUS has become more widely used in setting outside of the ER. When a medical emergency is occurring and time is of the essence, POCUS can help save lives by providing additional critical information to the physician as a Clinical Decision Support System. Technologies such as MediScan, which provides highly precise HD scans in under three minutes, can minimize the time before diagnosis and the start of treatment. MediScan’s propriety technology uses scans from ultrasound machines to reconstruct the analog two-dimensional grayscale visual image into a digital three-dimensional, high-definition quantifiable format. This groundbreaking technology, when combined with appropriate portable equipment, means that diagnosis can even be performed in the ambulance on the way to the hospital or in other locations that may have need of quick, accurate ultrasounds. The Mediscan software application dramatically increases the medical professional’s ability to use existing ultrasound devices at the point of care to derive meaningful data-driven clinical evaluations of a patient’s pathology or trauma, facilitate support for treatment options, monitor the patient’s ongoing progress or regress, and document compliance with required protocols and procedures. The Mediscan application also integrates with all popular EMR systems. For more information, visit the company’s website at www.MyMediScan.com. NOTE TO INVESTORS: The latest news and updates relating to HLTT are available in the company’s newsroom at https://ibn.fm/HLTT

• Company signs MOU with Christina Lake Cannabis Corp. to develop, distribute TAAT proprietary product in Canadian market
• TAAT CEO calls Canada “ideal play” for expansion based on existing interest from legal-aged smokers across the country
• Canadian population has nearly identical smoking incidence rate to the U.S., with an estimated 15% of the population that smokes

With record-breaking sales in its first weekend of online sales and an enthusiastic response to its on-the-ground retail launch in Ohio, TAAT Lifestyle & Wellness (CSE: TAAT) (OTCQB: TOBAF) has signed a deal to take its flagship product — TAAT(TM), a tobacco-free, nicotine-free cigarette — into Canada (https://ibn.fm/c7WmP). The company announced that it has finalized a memorandum of understanding (“MOU”) with Christina Lake Cannabis Corp. (CSE: CLC) to develop and distribute its proprietary product in the Canadian market.

“We are very pleased to have partnered with CLC, giving us the opportunity to bring TAAT to legal-aged smokers in Canada, many of whom have shown great enthusiasm about the product,” said TAAT CEO Sett Coscarella. “During my time in the tobacco industry, it was widely known that Canada was an exceptionally complex region in which to do business because of challenging regulations. Likewise, for products such as TAAT, which utilize hemp, the licensing requirements frequently represent a barrier to entry, often requiring products to be made or distributed through a Licensed Producer such as CLC.

“We have contemplated several international markets to which TAAT could expand first, and I believe that Canada is the ideal play based on the existing interest we already have from legal-aged smokers across Canada, a positive relationship with CLC to develop and distribute the product on our behalf, and a marketplace where the affordable price point of TAAT adds to its value proposition as a better choice,” Coscarella concluded.

TAAT has seen impressive growth and success in just the few months since its novel product was unveiled late last year. Available in Original, Smooth and Menthol, TAAT the product was born from the desire many smokers have for a tobacco-free and nicotine-free alternative that still offers the sensation of smoking. TAAT launched its completely innovative product in Ohio, followed by an online store last month. Registering record sales almost immediately — the company reported sales of C$100,000 in the first five days of online availability — the product clearly fills a need shared by adult smokers around the world.

Studies show that the Canadian population has a nearly identical smoking incidence rate to the United States, with an estimated 15% of the population that smokes. Based on TAAT’s research and real-world experience, a sizeable segment of legal-aged smokers could prefer TAAT over their regular brand of tobacco cigarettes. In addition, TAAT’s lower price is another tempting reason for smokers to try the newest option in the world of smoking.

For more information, visit the company’s website at www.TAATGlobal.com.

NOTE TO INVESTORS: The latest news and updates relating to TOBAF are available in the company’s newsroom at https://ibn.fm/TOBAF

• NexTech AR Solutions Corp. recently announced it had joined the Interactive Advertising Bureau’s AR board
• This announcement comes at a time when NexTech has been focusing on AR advertising, as seen through the recent launch of its in-house ad network that is similar to Amazon’s and Walmart’s advertisement networks
• NexTech, through its Ad Network, will curate ads for each event based on the theme and will be a marketplace where marketers and advertisers meet their target audiences
• With the company projecting that its revenues will increase in 2021, the fact that the Ad Network has already begun generating ROI means that it is bound to contribute to this revenue growth

Augmented reality (“AR”) has become a real utility. Buoyed by its use in gaming and entertainment in 2019, AR usage has been on an upward trajectory and has now been more broadly adopted in other industries. As a result, a 2020 survey by VR Intelligence revealed that 65% of companies were developing AR solutions for enterprise use, while 37.4% worked on consumer products and software (https://ibn.fm/K2YrX). NexTech AR Solutions (CSE: NTAR) (OTCQB: NEXCF), which falls in the first category, recently launched its Ad Network and announced it had joined the Interactive Advertising Bureau’s (“IAB”) AR board. IAB is the leading trade association whose mandate is to empower the media and players in the marketing industry to thrive in the digital economy. Its membership comprises over 650 leading media companies, brands and technology firms responsible for selling, delivering and optimizing digital ad marketing campaigns. By joining IAB’s AR board, NexTech will work with industry peers to build industry standards for AR creative formats, performance benchmarking, measurement standards and privacy considerations. The membership came as NexTech launched its Ad Network, a private marketplace integrated into its hybrid and virtual experience platform that enables marketers and advertisers to meet their target audience more easily than before. Notably, the hybrid and virtual experience platform, launched in 2020, is one of NexTech’s four digital experience platforms, the others being AR Experiences, AR e-commerce and advertising, Hybrid and Virtual Events and Augmented Learning. These four platforms fall into the company’s four business segments, namely AR, e-commerce, virtual events, and 3D/AR advertising. The hybrid and virtual experience platform targets clients who need stunning virtual meetings, conferences, trade shows and AR experiences. Besides facilitating virtual events, the platform displays targeted ads, thereby promoting engagements and learning opportunities and ensuring advertisers and attendees interact. “Trade shows, consumer expos and professional conferences are the future of targeted, impactful advertising and offer incredibly cost-effective investment to brands,” Hareesh Achi, President of Advertising at NexTech AR, commented (https://ibn.fm/X8IJq). NexTech curates the ads for each event and subsequently integrates them within the event platform for viewing by attendees. The result is a seamless experience for the event organizers, event sponsors and attendees. For instance, NTAR could display targeted ads from Colgate if it were running a dental convention on its virtual events platform. “Our strategy,” Evan Gappelberg, NexTech CEO, explained (https://ibn.fm/Sk37B), “is to take our augmented reality tech stack and evolve them into our virtual and hybrid events platform by first building advertising tools for ourselves but then building a self-serve ad tool for everyone and by providing a distribution channel to a captive audience on our platform.” He continued, “With today’s announcement of the successful market launch of our Ad Network, which is capable of 2D, 3D or AR ads, we’ve laid a foundation for this to happen.” Gappelberg likened NexTech’s approach to its Ad Network to Amazon’s (https://ibn.fm/XtfTP). “When you think of our Ad Network, it’s something that we’re integrating into our own platforms. It’s a very big deal. It’s exactly what Amazon is doing with their ad network, and Amazon generated $8 billion a quarter with their ad network,” he said in a presentation to investors. AR advertising holds many advantages for the advertisers as it increases engagements by 20% and conversion rates by between 90% and 200% (https://ibn.fm/fnTV5). By integrating this form of advertising into its platform, NexTech ensures that advertisers experience additional benefits as well. For instance, the platform provides a closed-loop attribution and a clean line of sight into high purchasing power and decision-making individuals. This makes tracking high ROI easy. Hailed as a powerful in-house advertising network for advertisers, brands and sponsors, Ad Network has already begun generating significant ROI for NexTech and is bound to contribute to the forecasted revenue increase. According to Gappelberg, the company’s revenue is projected to increase from $20 million in 2020 to between $50 and $60 million in 2021. For more information, visit the company’s website at www.NextechAR.com. NOTE TO INVESTORS: The latest news and updates relating to NEXCF are available in the company’s newsroom at https://ibn.fm/NEXCF

• Asia Broadband Inc. entered into an advanced collaboration with Core State Holdings Corp. for the production of its white-label gold-backed cryptocurrency coin
• AABB announced CSHC is moving through the final stages of testing of the iOS and Android AABB Wallet applications
• The company is working on a robust marketing campaign with CSHC for the expansion of the AABB Gold token, the AABB Wallet, and the brand as a whole

Asia Broadband (OTC: AABB) is a company engaged in the production of natural resources, and subsequently the supply and sale of base and precious metals, mainly to the Asian markets. Asia Broadband leverages its industry contacts to facilitate a streamlined distribution process from its production and supply unit in Mexico to client networks in Asia. The company’s vertical integration approach to sales transactions, coupled with geographical expertise and experience differentiates Asia Broadband from its competitors.

Asia Broadband recently announced a development update on the production of its white-label gold-backed cryptocurrency coin. The AABB stated that crypto wallet creation company Core State Holdings Corp. has scaled up its processing capacity and is working through the final stages of testing of the iOS and Android AABB Wallet applications. The application interface will allow users to see the real-time exchange rate of gold that backs the price of the AABB Gold token set at one-tenth of a gram or approximately 5.80 USD.

AABB entered into an advanced collaboration with Core State Holdings Corp., a digital assets and crypto wallet creator for producing AABB Gold token, an ERC-20 token is developed on the Ethereum blockchain.

CSHC intensified its operations owing to the heavy public response and high rate of token inquiries. AABB and CSHC have also set up a support system for conducting seamless communications. Further, the digital assets company leveled up the testing protocols to initiate smooth transaction processing when the token is ready for launch (https://ibn.fm/iGyjq).

AABB GoldToken.com is the go-to website for all information regarding the soon-to-be-launched AABB Wallet and AABB Gold token (“AABBG”). CSHC regularly updates the website with information regarding the latest developments.

As a part of its agreement deal with CSHC, AABB is working on a robust marketing campaign for the expansion of the corporate brand, the AABB Gold token, and the AABB Wallet. AABB envisages establishing the gold token as a secure and trusted worldwide standard of exchange by expansion into high-growth target markets including China and East Asia.

For more information, visit the company’s website at www.AsiaBroadbandInc.com.

NOTE TO INVESTORS: The latest news and updates relating to AABB are available in the company’s newsroom at https://ibn.fm/AABB

• COVID-19 has increased the need for disposable neurological technology
• Currently no way exists to ensure electrodes are free of contamination when using traditional reusable EEGs
• Neurological manifestations have presented themselves in 82% of hospitalized COVID-19

Brain Scientific (OTCQB: BRSF) is a commercial-stage, health-care company modernizing the brain diagnostic market through cutting-edge technologies. The company is fulfilling a growing need for improved brain monitoring that is cost efficient, disposable and portable. Neurological conditions are on the rise, increasing the need for an already sparse supply of specialized neurologists.

COVID-19 has increased the need for disposable neurological technology that is accessible to all. Traditional reusable EEG electrodes, even when cleaned, may still have microscopic traces of bacteria.

“Even when we follow all aspects of high-level disinfecting for our reusable products, there are so many nooks and crannies on the electrodes that there is no way to ensure that an electrode is completely free of any risk of contamination,” says Leah Hanson, R.EEG/EP T, vice president of global sales and marketing at Rhythmlink International, a medical equipment manufacturer (https://ibn.fm/1F1O8).

When combating a highly contagious disease, disposable technology ensures that the virus is not spread through equipment. Brain Scientific’s single-use, disposable EEG caps also shorten person-to-person contact due to ease of placement, decreasing transmission between staff and patient.

“As health-care facilities and frontline workers move quickly to address COVID symptoms and provide effective treatment, disposable devices offer a solution to rapidly and safely assess neurological changes in these patients,” wrote Brain Scientific co-founder and executive chairman Boris Goldstien in a recent “Pharma Mirror” article (https://ibn.fm/eMaUx). “Disposable EEG headsets are a cost-effective, readily-available solution that can be adopted for widespread use in these facilities during the current pandemic and moving forward to help healthcare workers gain a quick, reliable picture of a patient’s condition and receive treatment insights”

COVID-19 has also increased the need for neurological studies and long-term care. Neurological manifestations have presented themselves in 82% of hospitalized COVID-19 patients during the disease course. With a shortage of neurologists and accredited EEG technicians, the gap for needed medical care is widening. Brain Scientific’s disposable EEG’s provide an efficient means to collect results. Set-up takes roughly five minutes, compared to the 45-minute set-up of traditional sensors and does not require a skilled technician. Nurse practitioners, physicians and staff can administer the test.

Now that the virus has been in known existence for more than a year, studies are beginning to emerge describing long-term effects, including cognitive impairment lingering. A study conducted in Italy saw one-third of patients hospitalized with COVID-19 presenting abnormalities on neurologic exams six months later. These abnormalities included cognitive deficits, hyposmia, postural tremors, fatigue, memory impairment, depression/anxiety and sleep disorders (https://ibn.fm/TXZZ4).

More long-term studies are needed to fully understand the impact of COVID-19 on the brain.

To learn more about this company, visit www.BrainScientific.com/Invest-Now.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• Autonomous security robot (“ASR”) developer Knightscope is focused on a mission of making the United States more secure, particularly in the wake of some very recognizable national threats
• The company’s three ASR models help to secure the perimeter in business offices, government buildings, outdoor public venues and inside healthcare facilities
• The ASRs provide non-human capacity to avoid boredom on the job, be sickened by other people and suffer deadly injuries from violent criminals
• The unarmed sentinels are designed to identify, record and relay significant information to human personnel

Perimeter security is the first key to defending property integrity for nearly everyone, from private homeowners to corporate businesses, as well as for temporary event managers such as race directors and government military mobile command members. Perimeter defense in the form of the private security industry needs to be able to deal with a variety of challenges that may include trespassers from outside the infrastructure and employee inattention within the infrastructure. Autonomous Security Robot (“ASR”) developer Knightscope has built its mission and technological platform on what it sees as a need to improve how perimeter security is maintained within the United States. “We are on a mission to make the United States of America the safest country in the world. Yes, it is an audacious goal. But since when in our country do we shy away from what is hard and what is difficult? We are Americans,” a company video states (https://ibn.fm/k4RrK). The patriotic tone of the promotion underscores national concerns that came into clear focus 20 years ago when terrorists from other countries hijacked a handful of airplanes crossing American soil and turned them into weapons of terrible destruction that cost a large number of lives, and then when someone used the postal system immediately afterward to mail out letters tainted with a deadly biological pathogen to numerous people. More recently, similar concerns arose when political protests in the nation’s capital led to a riotous invasion of the halls of Congress in January, with threats against elected officials and a few deaths resulting from the incident. “Each (Knightscope robot) proudly displays the stars and stripes, signifying our patriotic duty to our country,” CEO William Santana Li says as he promotes the company’s mission to serve the United States in an investor relations video (https://ibn.fm/5To14). The company has introduced three models of ASRs thus far for patrolling indoor and outdoor locations. The company notes its robots are unsleeping “knights” that cannot be harmed by COVID or other human-borne viruses, or bored by lengthy periods of uneventful activity, or irreplaceably mortally wounded by malcontents. Knightscope’s ASRs also can come equipped with the ability for enhanced surveillance in total darkness using infrared and thermal cameras in tandem to observe and record activity that might not otherwise be visible (https://ibn.fm/Qdd4s). While the ASRs are not designed as armed mechanisms such as those portrayed as deadly AI machines in science fiction, or even as weaponized drones controlled by humans in military use, they are nevertheless useful in their AI-enhanced capacity of identifying people and select objects, such as license plates, and then alerting human controllers with recorded information as necessary. The ASRs have even been lauded after a heat-recognizing camera detected a spike in temperatures within a building and was able to summon intervention before a fire could create large-scale damage. Knightscope has topped 20,000 investors since rolling out its first autonomous product in 2015, utilizing a Reg A+ offering that allows Knightscope to attract private investments from both accredited and unaccredited investors (https://ibn.fm/04ZG5). For more information, visit the company’s website at www.Knightscope.com. Visit www.Knightscope.com/invest for a summary of Knightscope as an investment, with a blue Instant Messaging button for direct contact with their CEO. DISCLAIMER: You should read the Offering Circular and risks related to this offering before investing. This Reg A+ offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/Knight

• IAEA report notes that an adequate supply of uranium will be vital as nuclear power continues to provide an important source of the world’s carbon-free energy
• “Undiscovered resources must be converted to discoveries, which must then be developed in a timely matter,” report concludes
• UEC is focused on expanding uranium production while developing a pipeline of low-cost resources for major ongoing growth

A recent analysis of the world’s uranium supply by the International Atomic Energy Agency (“IAEA”) states that nuclear power will be a primary source of energy for the world in the coming years — assuming an adequate supply of uranium can be maintained (https://ibn.fm/ra0Vo). That report is great news for Uranium Energy (NYSE American: UEC), a U.S.-based uranium mining and exploration company that controls one of the country’s largest historical uranium exploration and development databases. UEC leverages this invaluable data to target and acquire properties that have been subject to exploration and development by senior energy firms in the past and that are ideally positioned to become major supplies of uranium in the coming years.

“Nuclear power is expected to be an important part of the worldwide energy mix at least through the next 50 years and by most projections well beyond,” the IAEA study reported. “That is, of course, provided an adequate supply of uranium is available to sustain the nominal growth rate for nuclear power of 1 to 3% per year that is projected by many analysts. The importance that a reliable supply will have on the future of nuclear power led the IAEA to undertake a study of uranium supply-demand relationships through 2050.”

The detailed report evaluates the adequacy of the world’s uranium supply to meet demand. The paper analyzes the supply of uranium given different levels of demand, ultimately concluding that “by 2025, primary supply sources are expected to cover 94% of requirements, and the role of Market-based Production is projected to grow from satisfying 45% of requirements in 2000 to 86% in 2025. Known resources are adequate to cover about 96% of Market-based Production requirements in the middle demand case. However, because of resource distribution and production capacity limitations, not all resources will have been depleted by 2050, leaving a cumulative deficit between production and requirements of nearly 850 000 t U. This deficit expands 3.5-fold in the high demand case. Even with the addition of undiscovered EAR-II, there will still be a deficit between production and Market-based Production requirements of about 307 000 t U in the middle demand case.

“The challenge for the uranium production industry will be to discover large, relatively low-cost deposits to fill the projected deficits,” the study concludes. “Plentiful secondary supply has depressed uranium market prices, which in turn has diminished incentive to undertake the exploration programmes needed to offset these deficits. . . . There is not a true shortage of potential resources. However, these undiscovered resources must be converted to discoveries, which must then be developed in a timely manner to ensure that their resources can be fully utilized to offset the projected deficits.”

UEC is focused on doing just that. The company’s mission — to expand uranium production using low-cost in-situ recovery (“ISR”) while developing a pipeline of resources for major ongoing growth — dovetails perfectly with the report from the IAEA noting the need for promising projects to be fully developed. The U.S. Geological Survey recently reported to the International Atomic Energy Agency that South Texas represents one of the world’s most prospective regions for new uranium discovery and development. Uranium Energy Corp has a strong presence in South Texas with the infrastructure in place to capitalize on the region for further exploration, development and production.

UEC discovered the Burke Hollow project in South Texas, and in a recent press release, their vice president of Resource Development stated, “…the extensive, lightly-explored trend extensions and remaining undrilled areas of the project have the potential to be the largest Goliad Formation deposit discovered to date in the South Texas Uranium Belt.” Uranium Energy Corp has the largest resource base of fully permitted projects in Texas and Wyoming of any U.S.-based producer.  The company is well positioned to supply the U.S. strategic Uranium Reserve as well as utility demand. UEC also has additional U.S. projects in their pipeline in New Mexico, Arizona, Colorado, and other projects in Canada and Paraguay. UEC is committed to providing low-cost, environmentally friendly uranium for the safe, highly reliable carbon-free energy that nuclear power provides.

For more information, visit the company’s website at www.UraniumEnergy.com.

NOTE TO INVESTORS: The latest news and updates relating to UEC are available in the company’s newsroom at https://ibn.fm/UEC

• BRSF signed MOU with leading provider of digital therapeutics for mental health sector to use data, AI to advance work in mental health disorders
• Company will provide proprietary NeuroCap, NeuroEEG devices to collect, transfer data from patients
• Collaboration could expand into a number of clinical and commercial applications

Brain Scientific (OTCQB: BRSF), a commercial-stage, health-care company developing products related to the brain including neurology, AI and machine learning, has signed a memorandum of understanding (“MoU”) with Ehave Inc. (OTC: EHVVF), a provider of digital therapeutics for the mental health sector (https://ibn.fm/ktiLG). The two companies aim to collaborate by using data and AI to correlate biomarkers to identify chronic pain, depression (major and persistent), PTSD, bipolar disorder, general anxiety, ADHD and schizophrenia. Brain Scientific and Ehave will team up to leverage graph-based AI and linked data protocols to develop neural net algorithms. These algorithms could be used to upload already trained neuronet into a specialized chip that Brain Scientific develops into a temporary e-tattoo or electrodes connected to the micro EEG positioned behind a patient’s ear. The brain e-tattoo is the BRSF’s new AI-powered, graphene-based solution that can process the signals from the sensors and wirelessly transfers data to a cloud application (https://ibn.fm/zcERv). Under the MOU, Brain Scientific would provide its proprietary data signal acquisition devices, NeuroCap(TM) and NeuroEEG(TM), for the Ehave platform. Ehave would integrate the devices to collect data from patients in real time and transfer that data into a cloud. NeuroCap is a patented, disposable EEG headset with 22 pre-gelled electrodes that anyone can set up in five minutes or less to record a patient’s brain activity. The cap is compatible with third-party amplifiers and the device also works with NeuroEEG, a proprietary portable, wireless, 16-channel amplifier that can easily be deployed across a broad spectrum of settings also requires minimal training. The devices allow for raw EEG data to be instantly transferred to a cloud, which enables remote access and interpretation by neurologists. These low-cost, portable and wireless devices provide the same quality of signal as conventional EEG devices and could be employed both in clinical and commercial settings. For example, one possible aspect of the collaboration could involve Ehave deploying NeuroCap and NeuroEEG in clinical settings with its partner healthcare providers such as psychiatrists, psychologists, psychotherapists and general practitioners. This would allow Ehave to collect the data representing electrophysiological changes in the brain before, during and after psychedelic drug administration. The MOU may also potentially lead to establishing or partnering with a lab that could be equipped with NeuroCap and NeuroEEG devices to conduct market studies to study consumer behavior and psychology in markets and capture data on different brain-related physiological and mental disorders. Likely to begin in Australia, this application could be rolled out in other locations where Ehave has a presence. The two collaborating companies will jointly own all data from any transactions arising from the MOU. Ehave will cover the testing and certification cost for products developed under the agreement and will receive full intellectual property rights, including the right to sell and distribute any such products, on a 50/50 split basis after all expenses, including research and development. To learn more about this company, visit www.BrainScientific.com/Invest-Now. NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• COVID-19 disease has shown propensity to affect patients’ long-term health by affecting cardiovascular and pulmonary systems
• Medical practitioners have increasingly turned towards ultrasound machines to scan critical organs while simultaneously limiting their exposure to potentially contagious patients
• Mediscan’s cloud-based ultrasound software allows medical professionals to accurately view and diagnose internal issues through 3D musculoskeletal, lung, cardiac imaging

COVID-19 has shown a propensity to affect an individual’s body in a number of different ways, including the long-term health of a patient’s cardiovascular and pulmonary system. As such, the need to properly diagnose lung infections, which could otherwise be sustained throughout a patient’s life, or myocarditis, an inflammation of the heart muscles which could go undiscovered if not properly diagnosed, has heightened the need for medical practitioners to make use of the proper technology to enable early diagnosis. Healthtech Solutions (OTC: HLTT), through its Mediscan Inc. subsidiary, has developed a cloud-based software for ultrasound technology which has proven to be highly effective in diagnosing internal organs potentially affected by COVID-19. Moreover, ultrasounds have also shown an ability to monitor a patient’s vital signs and single out any potential abnormalities. Ultrasound, a fast-evolving technology, can provide an immediate diagnosis of an internal issue in a patient’s body. When a symptomatic patient is suffering from COVID-19, bedside ultrasound is commonly used to scan critical organs, such as the heart, for damage (https://ibn.fm/BNrjM). Thus, ultrasounds can both avoid the need for patients to undergo potentially invasive physical examinations while simultaneously limiting the exposure to which medical practitioners may be subjected when dealing with the individual. Mediscan’s technology has shown great success in musculoskeletal (“MSK”), lung and cardiac imaging, enabling rapid pathology evaluation. Scanning the lung or the MSK sub-system, Mediscan directly images the target area being checked, saves it as a reference, and then automatically compares it to previous images. This enables it to determine the changes in a patient’s condition. In addition to its utility in MSK, lung and cardiac imaging, the use of portable ultrasounds equipped with Mediscan’s cloud-based software application provides healthcare providers with a flexible and easy-to-use solution through which to accurately evaluate, triage and diagnose COVID-19’s effects on contagious patients in isolation. This is particularly useful in situations where traditional MRI’s, CET or PET scans are otherwise not accessible. Traditional ultrasound technology has long relied on producing 2D-grayscale images, which Mediscan’s technology can transform into a digital 3D-HD format. Once an image has been captured in 2D, Mediscan’s software can convert it using its proprietary cloud-based software application process, providing medical professionals with 3D medical images of different organs, including the heart, lungs, tendons, skin and nerves. COVID-19 can vary in the way it affects the body, ranging from mild and negligible symptoms to much more life-threatening forms. However, in all cases, it is necessary to diagnose each patient and search for potential pulmonary or cardiac damage as a priority. An early diagnosis can play a critical role in ensuring a patient’s full recovery, with technologies like ultrasounds playing an increasingly important role. The widening scope of clinical applications for Mediscan’s ultrasound-based technology as well as its growing potential to serve as an early diagnosis tool for coronavirus-linked organ damage has further boosted the company’s growth prospects within the North American medical imaging market, an industry which boasted an addressable target market size of $134 billion as of 2020 (https://ibn.fm/TSPAW). For more information, visit the company’s website at www.MyMediScan.com. NOTE TO INVESTORS: The latest news and updates relating to HLTT are available in the company’s newsroom at https://ibn.fm/HLTT